This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Merck Sharp & Dohme Corp, Spain.
Reference
Salavert M, et al. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Advances in Therapy : 16 Oct 2018. Available from: URL: http://doi.org/10.1007/s12325-018-0813-y
Rights and permissions
About this article
Cite this article
Bezlotoxumab cost effective for C. difficile infection in Spain. PharmacoEcon Outcomes News 815, 4 (2018). https://doi.org/10.1007/s40274-018-5385-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5385-1